Quality & Patient Safety

New tuberculosis drug tested in Brazil passes early stages of process

Patient Safety Monitor: Global Edition, April 14, 2009

A new antibiotic aimed at shortening the time to cure tuberculosis (TB) has passed a key phase, according to The Australian. The new antibiotic, moxifloxacin, was added to the standard list of TB medications and given to a group of 170 patients in Brazil.

The normal course of treatment for TB lasts for six months of prescribed medications. Due to such a long period of treatment, many TB patients desert the treatment once they are no longer displaying symptoms of the disease, and believe they are cured.

According to The Australian, the trial was a Phase II study, and 80% of the patients in Brazil who took moxifloxacin tested negative for the TB bacterium at the end of eight weeks, as opposed to only 63% who did not receive moxifloxacin.

To read more, click here.

Most Popular